검색어: mitratapide (영어 - 덴마크어)

mitratapide
mitratapid

mitratapide 5 mg/ml
mitratapid 5 mg/ml

mitratapide placebo mitratapide placebo
mitratapid placebo mitratapid placebo

mitratapide has no central effect.
mitratapid har ingen central virkning.

yarvitan 5 mg/ml oral solution for dogs mitratapide
yarvitan 5 mg/ml peroral opløsning til hunde mitratapid

laboratory animals and dogs rapidly absorb orally administered mitratapide.
laboratoriedyr og hunde absorberer hurtigt peroralt administreret mitratapid.

percentages of dogs per weight loss category for mitratapide versus placebo:
procenter af hunde pr. vægttabskategori for mitratapid versus placebo:

mitratapide therapy should be restricted to one treatment course for an individual dog.
mitratapidbehandling bør begrænses til ét behandlingsforløb for en individuel hund.

the absorption of lipid soluble drugs used concomitantly with mitratapide has not been investigated.
absorptionen af lipidopløselige lægemidler anvendt samtidig med mitratapid er ikke blevet undersøgt.

mitratapide is a potent inhibitor of the microsomal triglyceride transfer protein (mtp).
mitratapid er en potent hæmmer af det mikrosomale triglycerid transfer protein (mtp).

mitratapide also has a slight appetite decreasing effect, which is linked to its mode of action.
mitratapid har også en let appetitnedsættende virkning, hvilket er forbundet med dets virkningsmåde.

mitratapide and its metabolites bind very extensively (> 99 %) to plasma proteins and distribute to the tissues.
mitratapid og dets metaboliter bindes meget omfattende (> 99 %) til plasmaproteiner og fordeles til vævene.

mitratapide 5 mg/ ml butylated hydroxyanisole (e 320) yarvitan is a colourless to slightly yellow solution.
mitratapid 5 mg/ ml butyleret hydroxyanisol (e 320) en farveløs til let gullig opløsning.

the usual dose is once daily 0.63 mg mitratapide/kg bodyweight (1 ml of the product per 8 kg) .
den sædvanlige dosis er 0, 63 mg mitratapid/kg legemsvæg (1 ml af produktet pr.8 kg) én gang daglig.

the active substance in yarvitan, mitratapide, works in the gut by blocking a protein (the microsomal triglyceride transfer protein).
det aktive stof i yarvitan, mitratapid, virker i tarmen ved at blokere et protein (mikrosomalt triglycerid-transportprotein).

administer orally once daily at 0.63 mg mitratapide/kg bodyweight (1 ml of the product per 8 kg) given for 2 periods of 21 days with 14 days without treatment in between.
gives peroralt én gang daglig som 0, 63 mg mitratapid/kg legemsvægt (1 ml af produktet pr.8 kg) i 2 perioder på 21 dage med 14 dages mellemrum uden behandling.

following oral administration, the bioavailability of mitratapide (parent compound and metabolites) is in the range from 55 to 69%, the volume of distribution is approximately 5 l/kg.
efter peroral administration er biotilgængeligheden af mitratapid (moderforbindelsen og metaboliter) i området fra 55 til 69%, fordelingsvolumen er cirka 5 l/kg.